Thrombotic risk in dogs with primary immune-mediated haemolytic anemia under treatment with mycophenolate mofetila

• Grant number: 16/23403-1
• Support Opportunities: Scholarships in Brazil - Master
• Effective date (Start): March 01, 2017
• Effective date (End): July 31, 2018
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Acordo de Cooperação: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Regina Kiomi Takahira
• Grantee: Tatiana Geraissate Gorenstein
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Immunemediated hemolytic anemia (IMHA) is the most prevalent immune disorder among dogs. It is characterized as type II hypersensitivity, leading to premature destruction of red blood cells. Among the main complications, hypercoagulability predisposing to disseminated intravascular coagulation and pulmonary thromboembolism is the most important, being cause of death in more than 80% of the cases. The diagnosis is made by excluding other causes for anemia and the presence of one or more of these signs: moderate to severe anemia (hematocrit <25-35%), evidence of hemolysis (hemoglobinemia, hemoglobinuria or hyperbilirubinemia) and presence of antibodies in the erythrocyte (characterized from self-agglutination, spherocytosis, positive Coombs test or flow cytometry). Treatment is directed to suppression of the immune response, having corticosteroids and immunosuppressants as the drugs of predilection. The aim of this study is to clarify if there is a change in the thrombotic risk after the initiation of immunosuppressive therapy with mofetila mycophenolate through thromboelastometry. For this purpose, dogs with a primary IMHA diagnosis will be selected. They will be submitted to hemogram, reticulocyte count, spherocytosis screening, biochemical, urinalysis, urinary creatinine protein ratio, coagulation tests, thromboelastometry; PCR or serology for E. canis, B. canis, Leptospira spp and abdominal ultrasonography (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

GORENSTEIN, T. G.; PORTILHO, F. V. R.; CALOBRIZI, N. P.; GONCALVES, D. S.; PAES, A. C.; TAKAHIRA, R. K.. [Avaliação por tromboelastometria do efeito do micofenolato de mofetila no risco trombótico em cães com anemia hemolítica imunomediada primária e secundária à infecção por Erhlichia canis]. Arquivo Brasileiro de Medicina Veterinária e Zootecnia, v. 73, n. 2, p. 335-342, MAR-APR 2021. (16/23403-1)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

GORENSTEIN, Tatiana Geraissate. Trombotic risk in dogs with primary immune-mediated hemolytic anemia and secondary to E. canis under treatment with micofenolate mofetil. 2018. Master's Dissertation - Universidade Estadual Paulista (Unesp). Faculdade de Medicina Veterinária e Zootecnia. Botucatu Botucatu.